623 results about "Hypsarrhythmia" patented technology

The invented non-invasive vital signs monitor is in a flexible, nominally flat planar form having integral gel electrodes, a sticky-back rear surface, an internal flex circuit capable of sensing, recording and playing out several minutes of the most recently acquired ECG waveform data and a front surface that includes an outplay port. The invented non-invasive body composition ‘risk’ monitor includes a measurement device for monitoring one or more variables including body fluid mass, dehydration, respiratory rate, blood pressure, bio-impedance, cardiography such as cardiac output, and body conformation parameters. The risk monitor may be provided in a lightweight carrying case into which the vital signs monitor plugs. Finally, a lightweight portable probe or transducer containing a transmissive or reflective electro-optical emitter and receptor in the infrared spectrum is fitted on a subject's finger or toe. Associated electronics energize and monitor the probe, detect cardio-rhythmic fluctuations therefrom, and process digital data over a prescribed window to produce a non-invasive, qualitative or quantitative measure of the subject's circulation. In accordance with one embodiment of the invention, a simple tri-color LED array is used to indicate the subject's circulation as being normal, reduced, or borderline. Thus the vital signs, bio-impedance, and circulation monitors may be independent or they may be integrated into one portable, non-invasive device that can concurrently monitor and locally display or remotely convey important patient data including circulation data to a local subject or physician or to / from a remote patient medical data center via wireless telemetry for oversight, treatment and possible intervention by a remote physician.

Systems and methods of detecting an impending cardiac decompensation of a patient measure an electrocardiogram signal of the patient. An incidence of cardiac arrhythmias is determined from the electrocardiogram signal. A risk of impending decompensation is determined in response to the incidence of cardiac arrhythmias. In many embodiments, the impending decompensation can be detected early enough to avoid, or at least delay, the impending decompensation, such that patient trauma and / or expensive ICU care can be avoided. Although embodiments make specific reference to monitoring electrocardiogram and other physiological signals with an adherent patch, the system methods and devices are applicable to many applications in which physiological monitoring is used, for example wireless physiological monitoring with implanted sensors for extended periods.

An efficient system for diagnosing arrhythmias and directing catheter therapies may allow for measuring, classifying, analyzing, and mapping spatial electrophysiological (EP) patterns within a body. The efficient system may further guide arrhythmia therapy and update maps as treatment is delivered. The efficient system may use a medical device having a high density of sensors with a known spatial configuration for collecting EP data and positioning data. Further, the efficient system may also use an electronic control system (ECU) for computing and providing the user with a variety of metrics, derivative metrics, high definition (HD) maps, HD composite maps, and general visual aids for association with a geometrical anatomical model shown on a display device.

Different types of cardiac arrhythmia are classified based on the morphology of the arrhythmic beats. Cardiac beats associated with an arrhythmic episode are compared to a plurality of representative beat morphologies, each representative beat morphology characterizing a type of arrhythmia of the heart. An arrhythmic episode may be classified as a particular type of arrhythmia if the morphology of the arrhythmic cardiac beats matches a representative beat morphology characterizing the particular type of arrhythmia. An appropriate therapy for the particular type of arrhythmia may be selected based on the arrhythmia classification. A particular type of arrhythmia may be associated with one or more therapies used to treat the arrhythmia. The therapy used to treat the arrhythmia may comprise a therapy identified as a previously successful therapy.

Systems and methods that improving the specificity of discriminating between a monomorphic tachyarrhythmia and a polymorphic tachyarrhythmia are provided that examine frequency content and baseline information of the EGM as discriminatory signatures. Particular algorithms of the present invention that are employed to determine frequency content of the QRS complexes are titled the Slope Distribution Metric (SDM) algorithm and the Slope Distribution Composite (SDC) algorithm.

A method for diagnosing and mapping atrial fibrillation correlates recordings of electrical activity from intracardiac multielectrode catheters with the locations of electrodes within the heart to obtain a global mapping of cardiac electrical activity. Time delay and / or amplitude information in the recorded electrical activities is fused with electrode location information to generate a display on a 3-D anatomical template of the heart. Time delay and / or amplitude information is displayed using color code and / or lines of equal value, to aid diagnosis and localization of electrical activity irregularities. Mapping of atrial fibrillation enables physicians to treat arrhythmia by ablation, pacing, shock therapy and / or drugs at initiation or during an episode based on therapy delivery at critical mapped locations for arrhythmia onset or maintenance. Locations for placement of pacing leads and pacemaker timing parameters may also be obtained from the display.

The invention provides a non-invasive method for treatment of arrhythmia. In a first aspect, a method for treatment of atrial fibrillation in a heart of a patient comprises directing radiation from outside the patient toward one or more target treatment regions of the heart so as to inhibit the atrial fibrillation. The radiation may induce isolation of a pulmonary vein.

A device and method in which spectral analysis of heart rate variability is performed in order to assess autonomic balance. When a threshold level is reached, a diagnostic mode is triggered in which the device performs computationally intensive data analysis to assess the probability of a pathological event such as an arrhythmia occurring.

A resonant circuit is incorporated in a stent, which implantable in a pulmonary vein using known cardiac catheterization techniques. When an external RF field is generated at the resonant frequency of the stent, RF energy is re-radiated by the stent toward electroconductive tissue in the wall of the pulmonary vein, and produces a circumferential conduction block. The stent can be made of biodegradable materials, so that it eventually is resorbed. Following an ablation procedure, the stent may be left in situ. Repeated ablation can be performed using the inserted stent until it has been determined that the desired lesions have been formed. Furthermore, the same stent can potentially be used even years after being inserted should the treated arrhythmia reoccur or a new arrhythmia develop, thereby possibly obviating the need for an invasive procedure at that future time.